A Randomized, Placebo-Controlled Trial of HPV Vaccination to Reduce Cervical High-Grade Squamous Intraepithelial Lesions Among HIV-Infected Women Participating in an HPV Test-and-Treat Program (COVENANT)

Trial Profile

A Randomized, Placebo-Controlled Trial of HPV Vaccination to Reduce Cervical High-Grade Squamous Intraepithelial Lesions Among HIV-Infected Women Participating in an HPV Test-and-Treat Program (COVENANT)

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Jul 2018

At a glance

  • Drugs Human papillomavirus vaccine recombinant nonavalent Merck (Primary)
  • Indications Cervical cancer
  • Focus Therapeutic Use
  • Acronyms COVENANT
  • Most Recent Events

    • 12 Jul 2018 Planned initiation date changed from 1 Jun 2018 to 1 Oct 2018.
    • 09 Jan 2018 Planned initiation date changed from 1 May 2018 to 1 Jun 2018.
    • 09 Jan 2018 Planned initiation date changed from 1 Dec 2017 to 1 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top